Author

M. Wachtel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Organism:human· 3 Assay:scRNA-seq· 3 Approach:deep learning· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

A. G. Henssen· 2 shared D. Gürgen· 2 shared S. G. Danielli· 2 shared A. Eggert· 1 shared A. G. Patel· 1 shared A. J. De Micheli· 1 shared A. Kühl· 1 shared A. M. Wengner· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. G. Henssen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivOct 13, 2023

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma

S. G. Danielli, Y. Wei, M. A. Dyer…·D. M. Langenau

This study identifies therapy-resistant and tumor-acquired cell states in pediatric rhabdomyosarcoma using single-cell RNA sequencing.

DOI 10.1038/s41467-024-50527-2

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 10, 2022

Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models

F. F. Pusch, H. Dorado Garcia, R. Xu…·A. G. Henssen

This paper evaluates elimusertib's preclinical efficacy in pediatric solid tumor models, finding it outperforms standard chemotherapy, especially in alveolar rhabdomysarcoma.

DOI 10.1101/2022.11.10.515290

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 20, 2022

Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance

S. G. Danielli, E. Porpiglia, A. J. De Micheli…·B. W. Schäfer

This study maps tumor heterogeneity in pediatric rhabdomyosarcoma using single-cell data, revealing developmental signatures and identifying the RAS pathway as a therapeutic target.

DOI 10.1101/2022.04.20.487706

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 6, 2019

Miswired enhancer logic drives translocation positive rhabdomyosarcoma

B. E. Gryder, M. Wachtel, K. Chang…·J. Khan

The paper identifies a miswired enhancer logic driven by PAX3-FOXO1 translocation in rhabdomyosarcoma, disrupting normal transcription factor regulation and promoting undifferentiated proliferation.

DOI 10.1101/757369

𝕏 PostBluesky